Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
In patients with metastatic uveal melanoma, a combination of bevacizumab plus temozolomide achieved a 6‑month progression‑free rate of 23%.
Noncomparative phase II study evaluating bevacizumab (10 mg/kg on days 8 and 22) plus temozolomide (150 mg/m^2 days 1‑7 and 15‑21) in 36 patients with metastatic uveal melanoma. Primary endpoint: progression‑free rate (PFR) at 6 months. 6‑month PFR was 23% (95% CI 10‑39); median progression‑free survival 12 weeks, median overall survival 10 months. No unexpected toxicity; liver perfusion CT not predictive; VEGF‑A polymorphisms not correlated with outcome.
This study represents the first non‑comparative phase II trial of bevacizumab plus temozolomide as first‑line therapy in metastatic uveal melanoma, providing evidence that the combination has manageable toxicity but limited efficacy, thereby informing future trial design for this rare, aggressive cancer.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Uveal melanoma as a target for immune-therapy
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
- EORTC and Immunocore Announce Enrolment of First Patient onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
- Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer
- Custom bipolar electrode for bleomycin-based electrochemotherapy in patient-derived uveal melanoma in ovo and ex vivo